查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
罕见内分泌疾病治疗的全球市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按适应症、按药物类型、按给药方式、按分销管道、按地区
市场调查报告书
商品编码
1410592

罕见内分泌疾病治疗的全球市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按适应症、按药物类型、按给药方式、按分销管道、按地区

Rare Endocrine Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 170 Pages | 商品交期: 2-5个工作天内

价格
简介目录

肥胖现在被认为是全球性的流行病，它不仅影响多囊性卵巢症候群、甲状腺功能减退症等常见疾病，也影响下视丘疾病、库欣氏症候群等罕见疾病，与多种内分泌疾病密切相关，包括：

肥胖发生的机制因特定的内分泌疾病而异。 在罕见的内分泌疾病中，生长激素和甲状腺功能的相互作用至关重要，并且通常与脂肪生成和脂肪细胞分化的增强有关。

世界各地的研究人员正在积极评估罕见内分泌疾病的治疗策略，特别关注超重患者。 例如，纽卡斯尔大学的科学家热衷于评估肥胖发展的自然史，同时考虑各种病因因素。

儘管尚未实现全面评估，但研究人员正在努力扩大评估流程，排除常见的内分泌原因，为选择适当的治疗方法铺路。

内分泌疾病的罕见性给研究人员和临床医生收集足够的患者数据以进行稳健的临床试验带来了挑战。 内分泌基因组虚拟实验室 (endoVL) 透过提供对分析工具和广泛数据集的安全线上存取来应对这一挑战，从而实现协作研究以推进罕见内分泌疾病的诊断和治疗。

endoVL 登记了超过 8,500 例肾上腺肿瘤病例，使研究人员能够利用大型队列进行具有统计学意义的分析。 目前有超过25项endoVL大型临床试验正在进行中，涉及世界各地的研究团队。 这种合作研究工作具有巨大的潜力，可以释放全球罕见内分泌疾病治疗市场的新增长机会。

罕见的内分泌疾病通常会出现多重器官症状，由于独特的病理生理障碍，首先出现在眼睛中。 认识罕见内分泌疾病的眼部表现对于及时诊断、治疗和预防显着的发病率和死亡率至关重要。

生物技术和製药公司与医学研究人员一起，预计将重点解决罕见内分泌疾病的眼科表现，并加速这一重要领域的治疗开发和创新。

本报告调查了全球罕见内分泌疾病治疗市场，并提供了市场概况，以及按适应症、药物类型、给药方式、分销渠道、地区和进入市场的公司划分的趋势。提供了竞争资讯趋势等

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第三章2018-2031年全球罕见内分泌疾病治疗市场展望

  • 2018-2031 年全球罕见内分泌疾病治疗市场前景（依适应症、价值（百万美元）、数量（吨））
  • 2018-2031 年全球罕见内分泌疾病治疗市场前景，以药物类型、价值（百万美元）、数量（吨）划分
  • 2018-2031 年全球罕见内分泌疾病治疗市场前景（依给药方式、价值（百万美元）、数量（吨））
  • 2018-2031 年全球罕见内分泌疾病治疗市场前景（按分销管道划分）、价值（百万美元）、数量（吨）
  • 2018-2031 年全球罕见内分泌疾病治疗市场前景（按地区、价值（百万美元）、数量（吨））

第4章2018-2031年北美罕见内分泌疾病治疗市场前景

第五章欧洲罕见内分泌疾病治疗市场展望，2018-2031

第六章2018-2031年亚太地区罕见内分泌疾病治疗市场前景

第 7 章 2018-2031 年拉丁美洲罕见内分泌疾病治疗市场展望

第8章中东及非洲罕见内分泌疾病治疗市场前景，2018-2031

第九章竞争态势

  • 依给药模式和药物类型划分的热图
  • 按製造商和药物类型划分的热图
  • 2023 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • Novartis
    • Ipsen
    • Pfizer, Inc
    • Teva
    • EMD serono
    • Novo Nordisk
    • Eli Lilly
    • Shire
    • Amgen, Inc
    • Corcept Therapeutics
    • Novelion Therapeutics

第 10 章附录

简介目录

The global rare endocrine disease treatment market, intricately linked with obesity and endocrine disorders, is poised for moderate growth in the forecast period from 2024 to 2031, according to a recent research study conducted by Fairfield Market Research.

Endocrine Diseases and the Obesity Connection

Obesity, now considered a global pandemic, has been closely associated with a range of endocrine diseases, including both common conditions like polycystic ovarian syndrome and hypothyroidism, as well as rare ailments such as hypothalamic disorders and Cushing's syndrome.

The mechanisms underlying obesity development vary depending on the specific endocrine disorder. In the case of rare endocrine diseases, interactions with growth hormones and thyroid functions are pivotal, often coupled with increased adipogenesis and adipocyte differentiation.

Researchers Focus on Treatment Evaluation

Researchers worldwide are actively engaged in evaluating treatment strategies for rare endocrine diseases, with a particular emphasis on overweight patients. For instance, scientists at the University of Newcastle are diligently assessing the natural history of obesity development, taking into account the various etiological factors at play.

While a comprehensive evaluation has not yet been achieved, researchers are conducting laboratory tests and physical examinations to expand the evaluation process, ruling out common endocrine causes and paving the way for appropriate treatment selection.

Research Collaboration Revolutionizes Rare Endocrine Disease Treatment

The rarity of endocrine diseases poses challenges for researchers and clinicians in gathering sufficient patient data for robust clinical trials. The Endocrine Genomics Virtual Laboratory (endoVL) addresses this challenge by providing secure online access to analytical tools and extensive datasets, enabling collaborative efforts to advance the diagnosis and treatment of rare endocrine diseases.

With more than 8,500 registered cases of adrenal tumors, endoVL empowers researchers to leverage large cohorts for statistically significant analyses. Currently, more than 25 large-scale clinical trials are underway within endoVL, engaging research groups from around the world. This collaborative research effort holds immense potential to unlock new growth opportunities in the global rare endocrine disease treatment market.

Innovations in Ophthalmic Manifestations

Rare endocrine disorders often manifest multi-organ symptoms, initially appearing in the eyes through distinct pathophysiological disturbances. Recognizing ophthalmic manifestations of rare endocrine diseases is crucial for swift diagnosis, treatment, and the prevention of significant morbidity and mortality.

Biotechnology and pharmaceutical companies, alongside medical researchers, are expected to focus on addressing ophthalmic manifestations of rare endocrine diseases, fostering treatment developments and innovations in this critical area.

Key Players in Rare Endocrine Disease Treatment

Prominent companies contributing to advancements in rare endocrine disease treatment, as identified by PMR's report, include Novartis, Ipsen, Pfizer, Inc., Teva, EMD Serono, Novo Nordisk, Eli Lilly, Shire, Amgen, Inc., Corcept Therapeutics, and Novelion Therapeutics.

Notably, Spruce Biosciences, a clinical-stage biotechnology firm, recently received FDA orphan drug designation for its SPR001, a potential treatment for congenital adrenal hyperplasia (CAH), a rare endocrine disease.

Rare Endocrine Disease Treatment Market Segmentation

Indication

  • Acromegaly
  • Central Diabetes Insipidus
  • Ahumada-Del Castillo Syndrome
  • Hypoparathyroidism
  • Other Indications

Drug Type

  • Biologics
  • Organic Compounds

Mode of Administration

  • Injectables
  • Oral
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North Americ
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Table of Contents

1. Executive Summary

  • 1.1. Global Rare Endocrine Disease Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Acromegaly
      • 3.1.1.2. Central Diabetes Insipidus
      • 3.1.1.3. Ahumada-Del Castillo Syndrome
      • 3.1.1.4. Hypoparathyroidism
      • 3.1.1.5. Other Indications
  • 3.2. Global Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biologics
      • 3.2.1.2. Organic Compounds
  • 3.3. Global Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Injectables
      • 3.3.1.2. Oral
      • 3.3.1.3. Others
  • 3.4. Global Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Online Pharmacies
  • 3.5. Global Rare Endocrine Disease Treatment Market Outlook, by Region, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Acromegaly
      • 4.1.1.2. Central Diabetes Insipidus
      • 4.1.1.3. Ahumada-Del Castillo Syndrome
      • 4.1.1.4. Hypoparathyroidism
      • 4.1.1.5. Other Indications
  • 4.2. North America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biologics
      • 4.2.1.2. Organic Compounds
  • 4.3. North America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Injectables
      • 4.3.1.2. Oral
      • 4.3.1.3. Others
  • 4.4. North America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Online Pharmacies
  • 4.5. North America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.2. U.S. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.3. U.S. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.4. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.5. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.6. Canada Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.7. Canada Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.8. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Acromegaly
      • 5.1.1.2. Central Diabetes Insipidus
      • 5.1.1.3. Ahumada-Del Castillo Syndrome
      • 5.1.1.4. Hypoparathyroidism
      • 5.1.1.5. Other Indications
  • 5.2. Europe Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biologics
      • 5.2.1.2. Organic Compounds
  • 5.3. Europe Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Injectables
      • 5.3.1.2. Oral
      • 5.3.1.3. Others
  • 5.4. Europe Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
  • 5.5. Europe Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.2. Germany Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.3. Germany Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.4. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.5. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.6. U.K. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.7. U.K. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.8. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.9. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.10. France Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.11. France Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.12. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.13. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.14. Italy Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.15. Italy Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.16. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.17. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.18. Turkey Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.19. Turkey Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.20. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.21. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.22. Russia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.23. Russia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.24. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.25. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.26. Rest of Europe Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.27. Rest of Europe Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.28. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Acromegaly
      • 6.1.1.2. Central Diabetes Insipidus
      • 6.1.1.3. Ahumada-Del Castillo Syndrome
      • 6.1.1.4. Hypoparathyroidism
      • 6.1.1.5. Other Indications
  • 6.2. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biologics
      • 6.2.1.2. Organic Compounds
  • 6.3. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Injectables
      • 6.3.1.2. Oral
      • 6.3.1.3. Others
  • 6.4. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
  • 6.5. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.2. China Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.3. China Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.4. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.5. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.6. Japan Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.7. Japan Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.8. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.9. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.10. South Korea Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.11. South Korea Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.12. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.13. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.14. India Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.15. India Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.16. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.17. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.18. Southeast Asia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.19. Southeast Asia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.20. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Acromegaly
      • 7.1.1.2. Central Diabetes Insipidus
      • 7.1.1.3. Ahumada-Del Castillo Syndrome
      • 7.1.1.4. Hypoparathyroidism
      • 7.1.1.5. Other Indications
  • 7.2. Latin America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Biologics
      • 7.2.1.2. Organic Compounds
  • 7.3. Latin America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Injectables
      • 7.3.1.2. Oral
      • 7.3.1.3. Others
  • 7.4. Latin America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
  • 7.5. Latin America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.2. Brazil Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.3. Brazil Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.4. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.5. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.6. Mexico Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.7. Mexico Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.8. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.9. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.10. Argentina Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.11. Argentina Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.12. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Acromegaly
      • 8.1.1.2. Central Diabetes Insipidus
      • 8.1.1.3. Ahumada-Del Castillo Syndrome
      • 8.1.1.4. Hypoparathyroidism
      • 8.1.1.5. Other Indications
  • 8.2. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biologics
      • 8.2.1.2. Organic Compounds
  • 8.3. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Injectables
      • 8.3.1.2. Oral
      • 8.3.1.3. Others
  • 8.4. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
  • 8.5. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.2. GCC Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.3. GCC Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.4. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.5. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.6. South Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.7. South Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.8. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.9. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.10. Egypt Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.11. Egypt Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.12. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.13. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.14. Nigeria Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.15. Nigeria Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.16. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. by Mode of Administration vs by Drug Type Heatmap
  • 9.2. Manufacturer vs by Drug Type Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Novartis
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Ipsen
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Pfizer, Inc
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Teva
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. EMD serono
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Novo Nordisk
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Eli Lilly
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Shire
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Amgen, Inc
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Corcept Therapeutics
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Novelion Therapeutics
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development

9.5.12.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations